Novartis Gilenya proves superiority over glatiramer acetate in relapsing remitting MS

Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS

07:57 EDT 13 May 2019 | Pharmaceutical Business Review

The results demonstrated Gilenya 0.5mg’s superior efficacy over glatiramer acetate 20mg in reducing the annualized relapse rate (ARR), a key measure of disease activity, with a 40.7% relative

More From BioPortfolio on "Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS"